A randomized, double blind, placebo-controlled single ascending dose study of LY03003 in healthy volunteers

Trial Profile

A randomized, double blind, placebo-controlled single ascending dose study of LY03003 in healthy volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Mar 2016

At a glance

  • Drugs Rotigotine (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms 03003SAD
  • Sponsors Luye Pharma Group
  • Most Recent Events

    • 15 Mar 2016 New trial record
    • 11 Mar 2016 Data from this and another phase I trial (CTP 700241160) will support a New Drug Application (NDA) via a 505(b)(2) pathway to the US FDA for LY03003, according to a Luye Pharma Group Ltd. media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top